
Alnylam Eyes Cambridge Expansion Following $2B Blackstone Financing
Following Blackstone’s $2-billion investment in Alnylam Pharmaceuticals, the Cambridge, MA-based life sciences company said Monday it was in discussions with Blackstone portfolio company BioMed Realty about expanding its space.
Alnylam didn’t specify how large the expansion would be. The company has occupied 295,000 square feet at BioMed’s 675 W. Kendall St. in Cambridge since 2018, taking over space formerly occupied by Vertex.
The strategic collaboration with Blackstone Life Sciences includes $1 billion to buy 50% of the future royalties and commercial milestones of Alnylam’s high cholesterol treatment inclisiran—currently under review by the U.S. Food and Drug Administration—and up to $150 million to develop Alnylam’s cardiometabolic programs vutrisiran and ALN-AGT.
Blackstone’s GSO Capital Partners will also provide Alnylam with a term loan of up to $750 million. Additionally, Blackstone will buy $100 million worth of newly-issued Alnylam stock.
For comments, questions or concerns, please contact Paul Bubny